Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Phase of Trial: Phase I/II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
- Focus Adverse reactions
- 26 Jan 2017 Planned End Date changed from 1 May 2018 to 31 Dec 2018.
- 26 Jan 2017 Planned primary completion date changed from 1 May 2017 to 15 Apr 2018.
- 01 May 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.